In-depth analysis of the FRESCO study: a randomized, double-blind, phase III trial evaluating the efficacy and safety of fruquintinib in patients with 3+ line advanced colorectal cancer (CSCO 2017)

Shukui QIN*, Jin LI*, Yuxian BAI, Yanhong DENG, Lei YANG, Zhen-Dong CHEN, Haijun ZHONG, Rui-Hua XU, Hongmin PAN, Weijian GUO, Yongqian SHU, Ying YUAN, Jianfeng ZHOU, Nong XU, Tianshu LIU, Dong MA, Changping WU, Ying CHENG, Jian-Ming XU, Donghui CHEN, Wei LI, Sanyuan SUN, Zhuang YU, Peiguo CAO, Lin SHEN, Haihui CHEN, Jiejun WANG, Shubin WANG, Hongbing WANG, Songhua Fan, Ye Hua, Weiguo Su

 HMPL-013_Ph3_CRC_subgroup_CSCO_2017_thumb.png

 

Venue: Chinese Society of Clinical Oncology Annual Meeting in Xiamen, China

Session: Plenary Keynote Presentation

Presenter: Shukui Qin

Date: Wednesday, September 27, 2017

 

Download Presentation (PDF)